PDT Partners’s Inozyme Pharma INZY Stock Holding History

PDT Partners’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,273	Closed	-$42K	–	1050
2022 Q1	$42K	Buy	+10,273	New	+$60.5K	﹤0.01%	906

Other funds holding INZY

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PDT Partners's INZY Position: Q2 2022 in Review

PDT Partners sold out of Inozyme Pharma (INZY) in Q2 2022, closing a stake of 10,273 shares — an estimated $42K sold.

PDT Partners first reported a position in INZY in Q1 2022 and held it in 1 quarter. The position peaked at $42K in Q1 2022. 47 funds tracked by Wall St. Rank hold INZY as of Q2 2022.

PDT Partners reported no remaining Inozyme Pharma position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 10,273 Inozyme Pharma shares in Q2 2022, an estimated $42K.
PDT Partners first reported a position in Inozyme Pharma in Q1 2022 and held it in 1 quarter.
PDT Partners's Inozyme Pharma position peaked at $42K in Q1 2022.
47 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.